An open-label study was carried out in 2016 in britain to research the feasibility, safety and efficacy of psilocybin in managing clients with unipolar treatment-resistant depression with promising success; Even though the research was small and associated only twelve individuals, 7 of All those patients met official conditions for remission one 7